The NephJC shorts version of the Hypertension medication step-down in a nursing home population from NEJM
PISCES: El Resumen Visual
¿Quieres saber cómo el uso de aceite de pescado podría reducir los eventos cardiovasculares en hemodiálisis? 🐟 Se viene una discusión imperdible por #NephJC.
No olvides revisar el resumen visual realizado por Brian Rifkin.
PISCES: The Visual Abstract
Curious how n-3 PUFAs may cut serious cardiovascular events in dialysis? 🐟
A big signal, a big dose, and a big discussion ahead — don’t miss this #NephJC!
Check out the VA made by our master Brian Rifkin
ORIGIN 3 interim-story: atacicept in IgAN
Check out ORIGIN 3 recap: a 36-week, interim analysis of phase 3 trial of atacicept in IgAN! Thread by NephJC intern Marc Soco.
Attacking the Origin of IgAN: ORIGIN3 and Atacicept
ORIGIN-3: The Visual Abstract
ORIGIN-3: El Resumen Visual
ORIGIN-3 ha llegado a NephJC con atacicept en NIgA.
Un paso sólido hacia una terapia dirigida anti BAFF/APRIL, que aborda la fisiopatología desde su origen. ¡Las señales tempranas son prometedoras!
Revisa el resumen visual realizado por Clemens Weber
ASIs Advance: NephJC Shorts on BaxHTN
NephJC Shorts: The end of the Fluid Wars?
CONFIDENCE manifests: finerenone & empagliflozin – CKD power couple that’s redefining ‘renal romance’
Check out CONFIDENCE recap
A dose of CONFIDENCE: Building evidence for finerenone-empagliflozin synergy in diabetic kidney disease
Advance-HTN: Return of the systolic order – Lorundrostat’s role in restoring balance
Does Lorundrostat Effectively Lower Blood Pressure in Uncontrolled Hypertension?
Stunning visual abstract summarizing NEJM study, by Priti Meena
Is a lower BP the road to better outcomes in diabetes?
How low is too low for blood pressure? Will BPROAD get to the bottom of this issue?
Microvascular inflammation of kidney allografts
Microvascular inflammation from the perspective of a real unicorn: donor-specific antibodies with negative antibody mediated rejection 🦄
